Extraskeletal myxoid chondrosarcoma
MONDO:0012825A rare malignant soft tissue neoplasm of uncertain differentiation, characterized by the presence of chondroblast-like cells in a myxoid stroma and a multinodular growth pattern. The most common sites of involvement are the deep soft tissues of the extremities, particularly the thigh. It usually presents as an enlarging soft tissue mass. Patients may have long survivals, but local recurrences and metastases occur in approximately half of the cases. The most common site of metastasis is the lungs.
Also known as: extraosseous chondrosarcoma, extraskeletal chondrosarcoma, myxoid extraosseous chondrosarcoma, myxoid extraskeletal chondrosarcoma, EMC, chondrosarcoma, extraskeletal myxoid
2819 clinical trials for this condition and its sub-types, 7 tagged with Extraskeletal myxoid chondrosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Extraskeletal myxoid chondrosarcoma
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New radiation combo aims to shrink sarcomas before surgery
Disease control Recruiting nowThis study tests two types of radiation therapy—proton beam or advanced photon (IMRT)—given before surgery for retroperitoneal sarcoma, a rare tumor deep in the abdomen. The goal is to find the highest safe dose that can be delivered to high-risk areas of the tumor while protecti…
Phase 1/2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New pill shows promise in slowing rare Cancer's growth
Disease control Recruiting nowThis study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…
Phase 2 • Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC